A Facile Atom-Economic Synthesis of Imidazoles with Chalcogenophosphoryl Substituents via Free-Radical Addition of Secondary Phosphine Chalcogenides to 1-Vinylimidazoles

Nina K. Gusarova, Svetlana F. Malysheva, Nataliya A. Belogorlova, Lidiya N. Parshina, Boris A. Trofimov*

A. E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, 1 Favorsky Street, 664033 Irkutsk, Russian Federation

Fax +7(3952)419346; E-mail: boris_trofimov@irioch.irk.ru Received 13 February 2011; revised 31 March 2011

Abstract: Secondary phosphine sulfides and selenides react with 1vinylimidazoles under radical initiation conditions to give the corresponding anti-Markovnikov adducts in up to 98% yields.

Key words: 1-vinylimidazoles, phosphine sulfides, phosphine selenides, radical addition

The imidazole ring is found frequently in natural products and biologically active compounds¹ such as biotin, histamine, the essential amino acid histidine, and the pilocarpine alkaloids. Imidazole-tailored ionic liquids^{1f,2} and organic catalysts³ are other applications of imidazole derivatives. Significant interest has focused on the synthesis of functionalized imidazoles containing organophosphorus substituents that are used as polydentate ligands for the design of effective metal–complex catalysts.⁴ Recently, we reported the synthesis of 1-substituted imidazoles possessing phosphinyl moieties via radical addition of secondary phosphines to 1-vinylimidazoles.⁵

Herein, we report a strategy for the simple and atom-economic synthesis of novel families of functionalized imidazoles. To achieve this goal we have examined, for the first time, the reaction of 1-vinylimidazoles with secondary phosphine chalcogenides. These substrates were prepared from red phosphorus, styrenes and elemental chalcogens.⁶

Our experiments revealed that secondary phosphine sulfides 1 and 2 and phosphine selenides 3-5 reacted readily with 1-vinylimidazole (6), 2-methyl-1-vinylimidazole (7) and 1-vinylbenzimidazole (8) under UV irradiation, or in the presence of 2,2'-azobis(isobutyronitrile) (AIBN) at 65–70 °C to form regioselectively the corresponding anti-Markovnikov adducts **9a–k** in high yields (Table 1).

It is pertinent to mention that secondary phosphine oxides do not react with vinylimidazoles **6–8** under the above conditions.⁵ This fact correlates well with the low reactivity of secondary phosphine oxides in the presence of radical initiators⁷ due to the high P–H bond dissociation energy in the phosphoryl moiety.⁸

Analysis of the results obtained (Table 1), as well as published data,⁵ showed that the reactivities of secondary phosphine sulfides and phosphine selenides were higher than those of the corresponding phosphines. Hence, the reactions with phosphine chalcogenides 1-5 (Table 1) were complete within 1.5-4 hours; in contrast, the corresponding secondary phosphines required reaction times of 2-7 hours.⁵ To evaluate the comparative reactivity of these PH-adducts with vinylimidazoles under radical addition conditions, we studied the competitive reaction of bis(2-phenylethyl)phosphine (10) and bis(2-phenylethyl)phosphine sulfide (1) with 1-vinylimidazole (6). Thus, a solution of compounds 1, 6 and 10 (molar ratio = 1:1:1) in 1,4-dioxane was subjected to UV irradiation in a quartz tube under an argon atmosphere. The relative rates of conversion of PH-adducts 1 and 10, and formation of the corresponding imidazolylphosphine 11 and imidazolylphosphine sulfide **9a** (Scheme 1) were monitored by ³¹P NMR spectroscopy.



Scheme 1 Competitive reaction of secondary phosphine 10 and phosphine sulfide 1 with 1-vinylimidazole (6)

The data obtained proved that phosphine sulfide **1** was more active in the reaction with 1-vinylimidazole (**6**) than bis(2-phenylethyl)phosphine (**10**). In the first 30 minutes of the reaction the concentration of the formed tertiary phosphine sulfide **9a** was almost 1.80 times higher than that of tertiary phosphine **11**. After 60 minutes, this ratio increased to 2.10, and after 90 minutes to 2.75; the concentration of the initial phosphine sulfide **1** being diminished faster than that of secondary phosphine **10**. The higher reactivity of secondary phosphines in free-radical additions to the electron-rich double bond of vinyl ethers, under radical initiation, has been reported previously.⁹

To summarize, the reported free-radical addition of secondary phosphine sulfides and phosphine selenides to 1vinylimidazoles represents a simple and atom-economic synthesis of a novel family of functionalized imidazoles possessing chalcogenophosphoryl moieties. These com-

SYNTHESIS 2011, No. 11, pp 1777–1782 Advanced online publication: 05.05.2011 DOI: 10.1055/s-0030-1260025; Art ID: Z19311SS © Georg Thieme Verlag Stuttgart · New York

pounds are promising candidates for drug design and as polydentate ligands for the preparation of effective metal– complex catalysts. The reaction developed may be considered as a basic contribution to both imidazole and organophosphorus chemistry.

 Table 1
 Addition of Secondary Phosphine Chalcogenides 1–5 to Imidazoles 6–8^a



Synthesis 2011, No. 11, 1777–1782 © Thieme Stuttgart · New York



Table 1 Addition of Secondary Phosphine Chalcogenides 1-5 to Imidazoles 6-8^a (continued)

^a The ratio of PH-adduct–imidazole was 1:1. All experiments were carried out under an Ar atmosphere.

^b Yield of isolated product.

All reactions were carried out under an Ar atmosphere. 1,4-Dioxane was distilled and dried according to a standard procedure. Diphenylphosphine and 1-vinylimidazole (6) were obtained from Aldrich Chemical Co. Diphenylphosphine chalcogenides 2 and 5 were prepared by oxidation of diphenylphosphine with elemental S or Se powder in EtOH. 1-Vinylimidazole (6) was distilled under reduced pressure prior to use. 2-Methyl-1-vinylimidazole (7) and 1-vinylbenzylimidazole (8) were synthesized using literature methods.¹⁰

AIBN was recrystallized from EtOH prior to use. UV irradiation experiments were carried out using a 200 W mercury arc lamp. Melting points were recorded on a Stuart melting point apparatus and are uncorrected. IR spectra were obtained using Bruker Vertex 70 instrumentation. ¹H, ¹³C, ³¹P and ⁷⁷Se NMR spectra were recorded at 400.13, 100.62, 161.98 and 76.31 MHz, respectively, as CDCl₃ solutions, on a Bruker DPX-400 spectrometer. Chemical shifts are reported in δ (ppm) relative to the residual non-deuterated (CHCl₃)

Downloaded by: WEST VIRGINIA UNIVERSITY. Copyrighted material.

solvent signal (¹H, ¹³C) as the internal standard, or H_3PO_4 (³¹P) and Me_2Se (⁷⁷Se) as external standards. Elemental analyses were obtained using a ThermoFinnigan CHN Flash EA1112 analyzer.

Tertiary Phosphine Sulfides 9a–d and Phosphine Selenides 9e–k; General Procedure

A soln of phosphine chalcogenide **1–5** (1.0 mmol) and imidazole **6–8** (1.0 mmol) in 1,4-dioxane (0.5 mL) was irradiated (200 W Hg arc lamp) in a quartz ampoule (method A), or heated at 65–70 °C in the presence of AIBN (1% wt of the total mass of reactants) in a sealed ampoule (method B) (reaction times are given in Table 1). The reaction progress was monitored using ³¹P NMR spectroscopy; the disappearance of the signal due to the starting phosphine chalcogenides (20–24 ppm for sulfides **1–2** and 2–8 ppm for selenides **3–**5), and the appearance of a new resonance at 46–48 ppm and 30–36 ppm for the tertiary phosphine sulfides **9a–d** and phosphine selenides **9e–k**, being indicative of completion. The mixture was dissolved in Et₂O (3 mL), filtered through a layer of Al₂O₃ (activity level II, 0.5 cm), and the filter-bed washed with a mixture of hexane–Et₂O (3 mL, 1:1). The solvents were removed by distillation under reduced pressure to give phosphine chalcogenides **9a–k**.

[2-(1*H*-Imidazol-1-yl)ethyl]diphenethylphosphine Sulfide (9a)

Light-yellow oil; yield (method A): 361 mg (98%); yield (method B): 343 mg (93%).

IR (film): 3086, 3062, 2933, 1603, 1497, 1454, 1403, 1359, 1288, 1230, 1181, 1108, 1078, 1030, 965, 947, 907, 818, 753, 699, 663, 622, 597, 551, 497 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): $\delta = 1.91-2.17$ (m, 6 H, CH₂P), 2.83–2.88 (m, 4 H, CH₂Ph), 4.23–4.30 (m, 2 H, CH₂N), 6.89 and 7.03 (s, 2 H, H-4.5, imidazole), 7.13–7.27 (m, 10 H, Ph), 7.60 (s, 1H, H-2, imidazole).

¹³C NMR (100.62 MHz, CDCl₃): δ = 28.45 (CH₂Ph), 31.98 (d, ${}^{1}J_{P-C}$ = 47.8 Hz, PCH₂CH₂N), 33.30 (d, ${}^{1}J_{P-C}$ = 49.3 Hz, CH₂P), 41.10 (CH₂N), 118.82 (C-4, imidazole), 126.77 (*p*-C, Ph), 128.24 (*o*-C, Ph), 128.77 (*m*-C, Ph), 129.27 (C-5, imidazole), 137.08 (C-2, imidazole), 139.97 (d, ${}^{3}J_{P-C}$ = 12.7 Hz, *i*-C, Ph).

³¹P NMR (161.98 MHz, CDCl₃): δ = 46.21.

Anal. Calcd for $C_{21}H_{25}N_2PS$: C, 68.45; H, 6.84; N, 7.60; P, 8.41; S, 8.70. Found: C, 68.40; H, 6.89; N, 7.45; P, 8.13; S, 8.32.

[2-(2-Methyl-1*H*-imidazol-1-yl)ethyl]diphenethylphosphine Sulfide (9b)

Colorless crystalline solid; yield (method A): 367 mg (96%); mp 128-130 °C (hexane).

IR (KBr): 3064, 3026, 2997, 2931, 2868, 1602, 1523, 1497, 1453, 1424, 1357, 1286, 1271, 1230, 1142, 1110, 1072, 1020, 967, 944, 915, 803, 775, 729, 699, 676, 603, 552, 496 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): δ = 2.01–2.10 (m, 6 H, PCH₂), 2.40 (s, 3 H, Me), 2.87–2.89 (m, 4 H, CH₂Ph), 4.16–4.23 (m, 2 H, CH₂N), 6.81 and 6.89 (s, 2 H, H-4,5, imidazole), 7.14–7.23 (m, 10 H, Ph).

¹³C NMR (100.62 MHz, CDCl₃): δ = 12.84 (Me), 28.31 (CH₂Ph), 31.35 (d, ${}^{1}J_{P-C}$ = 47.8 Hz, PCH₂CH₂N), 33.10 (d, ${}^{1}J_{P-C}$ = 48.2 Hz, CH₂P), 39.85 (CH₂N), 118.96 (C-4, imidazole), 126.57 (*p*-C, Ph), 128.0 (*o*-C, Ph), 128.45 (C-5, imidazole), 128.60 (*m*-C, Ph), 139.76 (d, ${}^{3}J_{P-C}$ = 13.6 Hz, *i*-C, Ph), 144.06 (C-2, imidazole).

³¹P NMR (161.98 MHz, CDCl₃): δ = 46.10.

Anal. Calcd for C₂₂H₂₇N₂PS: C, 69.08; H, 7.11; N, 7.32; P, 8.10; S, 8.38. Found: C, 69.04; H, 7.09; N, 7.45; P, 8.30; S, 8.35.

[2-(1*H*-Benzo[*d*]imidazol-1-yl)ethyl]diphenethylphosphine Sulfide (9c)

Colorless crystalline solid; yield (method A): 381 mg (91%); mp 50–51 $^{\circ}\mathrm{C}$ (hexane).

IR (KBr): 3085, 3062, 3005, 2931, 2859, 1614, 1496, 1454, 1403, 1366, 1332, 1284, 1242, 1217, 1161, 1009, 946, 872, 864, 750, 699, 666, 612, 551, 496, 427 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): δ = 1.97–2.03 (m, 4 H, PCH₂), 2.23–2.28 (m, 2 H, PCH₂CH₂N), 2.75–2.84 (m, 4 H, CH₂Ph), 4.51– 4.59 (m, 2 H, CH₂N), 7.03 and 7.05 (m, 2 H, H-5,6, imidazole), 7.14–7.32 (m, 10 H, Ph), 7.43, 7.79 and 8.09 (m, 3 H, H-4,7,2, imidazole).

¹³C NMR (100.62 MHz, CDCl₃): δ = 28.59 (CH₂Ph), 30.01 (d, ¹ J_{P-C} = 49.6 Hz, PCH₂CH₂N), 33.62 (d, ¹ J_{P-C} = 52.4 Hz, CH₂P), 39.38 (CH₂N), 109.75 (C-7, imidazole), 120.54, 122.89 and 123.62 (C-4, 6, 5, imidazole), 126.80 (*p*-C, Ph), 128.31 (*o*-C, Ph), 128.83 (*m*-C, Ph), 133.05 (C-8, imidazole), 140.02 (d, ³ J_{P-C} = 12.0 Hz, *i*-C, Ph), 143.25 and 143.36 (C-2,9, imidazole).

³¹P NMR (161.98 MHz, CDCl₃): δ = 47.57.

Anal. Calcd for $C_{25}H_{27}N_2PS$: C, 71.74; H, 6.50; N, 6.69; P, 7.40; S, 7.66. Found: C, 71.69; H, 6.49; N, 6.65; P, 7.36; S 7.54.

[2-(1*H*-Imidazol-1-yl)ethyl]diphenylphosphine Sulfide (9d) Light-yellow oil; yield (method A): 294 mg (94%).

IR (film): 3139, 3054, 2923, 2852, 1672, 1586, 1509, 1481, 1437, 1400, 1181, 1105, 1035, 1021, 997, 845, 747, 709, 694, 628, 611, 560, 509, 492 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): δ = 2.88–2.95 (m, 2 H, CH₂P), 4.36–4.42 (m, 2 H, CH₂N), 6.84 and 6.87 (s, 2 H, H-4,5, imidazole), 7.42–7.78 and 7.75–7.80 (m, 10 H, Ph), 7.87 (s, 1 H, H-2, imidazole).

¹³C NMR (100.62 MHz, CDCl₃): δ = 33.79 (d, ¹*J*_{P-C} = 53.8 Hz, CH₂P), 42.49 (CH₂N), 120.00 (C-4, imidazole), 128.77 (d,²*J*_{P-C} = 12.5 Hz, *o*-C, Ph), 130.00 (C-5, imidazole), 130.80 (d,³*J*_{P-C} = 11.3 Hz, *m*-C, Ph), 131.13 (d, ¹*J*_{P-C} = 87.4 Hz, *i*-C, Ph), 131.94 (*p*-C, Ph), 136.81 (C-2, imidazole).

³¹P NMR (161.98 MHz, CDCl₃): δ = 39.17.

Anal. Calcd for $C_{17}H_{17}N_2PS$: C, 65.37; H, 5.49; N, 8.97; P, 9.92; S, 10.27. Found: C, 65.31; H, 5.48; N, 8.90; P, 9.90; S, 10.20.

[**2-(1***H***-Imidazol-1-yl)ethyl]diphenethylphosphine Selenide (9e)** Light-yellow oil; yield (method A): 407 mg (98%); yield (method B): 332 mg (80%).

IR (film): 3107, 3062, 3003, 2932, 1602, 1497, 1454, 1402, 1359, 1323, 1230, 1150, 1108, 1077, 1030, 965, 907, 818, 753, 699, 662, 621, 573, 495, 470, 454 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): $\delta = 2.02-2.23$ (m, 6 H, CH₂P), 2.82-2.91 (m, 4 H, CH₂Ph), 4.27-4.31 (m, 2 H, CH₂N), 6.90 and 7.03 (s, 2 H, H-4,5, imidazole), 7.14-7.30 (m, 10 H, Ph), 7.56 (s, 1 H, H-2, imidazole).

¹³C NMR (100.62 MHz, CDCl₃): δ = 29.22 (CH₂Ph), 31.30 (d, ¹J_{P-C} = 40.5 Hz, PCH₂CH₂N), 32.85 (d, ¹J_{P-C} = 41.7 Hz, CH₂P), 41.98 (CH₂N), 118.75 (C-4, imidazole), 126.77 (*p*-C, Ph), 128.23 (*o*-C, Ph), 128.78 (*m*-C, Ph), 129.64 (C-5, imidazole), 137.13 (C-2, imidazole), 139.69 (d, ³J_{P-C} = 13.1 Hz, *i*-C, Ph).

³¹P NMR (161.98 MHz, CDCl₃): δ = 35.28 (s + d satellites, ¹*J*_{P-Se} = 710 Hz).

⁷⁷Se NMR (76.31 MHz, CDCl₃): $\delta = -392.10$ (d, ¹ $J_{P-Se} = 710$ Hz).

Anal. Calcd for C₂₁H₂₅N₂PSe: C, 60.72; H, 6.07; N, 6.74; P, 7.46; Se, 19.01. Found: C, 60.60; H, 6.09; N, 6.45; P, 7.30; Se, 18.92.

[2-(1*H*-Benzo[*d*]imidazol-1-yl)ethyl]diphenethylphosphine Selenide (9f)

Colorless crystalline solid; yield (method A): 442 mg (95%); mp 105–106 $^{\circ}\mathrm{C}$ (hexane).

IR (KBr): 3084, 3057, 2919, 2862, 1601, 1496, 1453, 1444, 1383, 1362, 1331, 1282, 1251, 1220, 1197, 1162, 1010, 956, 866, 842, 770, 761, 741, 699, 653, 626, 570, 452 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): δ = 2.04–2.10 (m, 4 H, PCH₂), 2.27–2.34 (m, 2 H, PCH₂CH₂N), 2.72–2.82 (m, 4 H, CH₂Ph), 4.49– 4.56 (m, 2 H, CH₂N), 7.00 and 7.02 (s, 2 H, H-5,6, imidazole), 7.16– 7.27 (m, 10 H, Ph), 7.40, 7.77 and 8.00 (m, 3 H, H-4,7,2, imidazole).

¹³C NMR (100.62 MHz, CDCl₃): $\delta = 29.14$ (d, ¹*J*_{P-C} = 40.7 Hz, PCH₂CH₂N), 29.16 (CH₂Ph), 33.87 (d, ¹*J*_{P-C} = 41.4 Hz, CH₂P), 40.09 (CH₂N), 109.49 (C-7, imidazole), 120.54, 122.55 and 123.29 (C-4, 6, 5, imidazole), 126.66 (*p*-C, Ph), 128.17 (*o*-C, Ph), 128.71 (*m*-C, Ph), 132.87 (C-8, imidazole), 139.55 (d, ³*J*_{P-C} = 13.2 Hz, *i*-C, Ph), 143.05 and 143.62 (C-2, 9, imidazole).

³¹P NMR (161.98 MHz, CDCl₃): δ = 35.59 (s + d satellites, ¹*J*_{P-Se} = 715 Hz).

⁷⁷Se NMR (76.31 MHz, CDCl₃): δ = -388.10 (d, ¹*J*_{P-Se} = 715 Hz).

Anal. Calcd for $C_{25}H_{27}N_2PSe: C, 64.51; H, 5.85; N, 6.02; P, 6.65; Se, 16.96. Found: C, 64.50; H, 5.82; N, 6.00; P, 6.63; Se, 16.92.$

[2-(1*H*-Imidazol-1-yl)ethyl]bis[4-(*tert*-butyl)phenethyl]phosphine Selenide (9g)

Light-yellow oil; yield (method A): 506 mg (96%).

IR (film): 3095, 3055, 2963, 2867, 1709, 1509, 1463, 1444, 1404, 1394, 1364, 1269, 1219, 1140, 1108, 1079, 1019, 963, 817, 756, 663, 622, 564, 484 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): δ = 1.26 (s, 18 H, Me), 2.07–2.25 (m, 6 H, CH₂P), 2.80–2.86 (m, 4 H, CH₂Ph), 4.25–4.32 (m, 2 H, CH₂N), 6.88 and 7.02 (s, 2 H, H-4,5, imidazole), 7.09 and 7.27 (m, 8 H, Ph), 7.57 (s, 1 H, H-2, imidazole).

¹³C NMR (100.62 MHz, CDCl₃): δ = 28.66 (*C*H₂Ph), 31.14 (d, ¹*J*_{P-C} = 40.0 Hz, P*C*H₂CH₂N), 31.24 (Me), 32.63 (d, ¹*J*_{P-C} = 40.7 Hz, CH₂P), 34.34 (*C*Me), 41.95 (CH₂N), 118.76 (C-4, imidazole), 125.61 (*o*-C, Ph), 127.87 (*m*-C, Ph), 129.42 (C-5, imidazole), 136.54 (d, ³*J*_{P-C} = 15.9 Hz, *i*-C, Ph), 137.03 (C-2, imidazole), 149.61 (*p*-C, Ph).

³¹P NMR (161.98 MHz, CDCl₃): δ = 35.58 (s + d satellites, ¹*J*_{P-Se} = 708 Hz).

⁷⁷Se NMR (76.31 MHz, CDCl₃): $\delta = -392.1$ (d, ¹*J*_{P-Se} = 708 Hz).

Anal. Calcd for $C_{29}H_{41}N_2PSe: C, 66.02; H, 7.83; N, 5.31; P, 5.87; Se, 14.97. Found: C, 66.00; H, 7.80; N, 5.32; P, 5.56; Se 14.72.$

Bis[4-(*tert*-butyl)phenethyl][2-(2-methyl-1*H*-imidazol-1-yl)eth-yl]phosphine Selenide (9h)

Colorless crystalline solid; yield (method A): 531 mg (98%); mp 95–96 °C (hexane).

IR (KBr): 3092, 3054, 2963, 2904, 2865, 1577, 1501, 1454, 1426, 1363, 1269, 1214, 1145, 1108, 1073, 1021, 1000, 977, 871, 854, 840, 773, 734, 677, 571, 560, 523, 482, 462 cm⁻¹.

 ^1H NMR (400.13 MHz, CDCl₃): δ = 1.27 (s, 18 H, Me), 2.13–2.22 (m, 6 H, CH₂P), 2.41 (s, 3 H, Me), 2.81–2.88 (m, 4 H, CH₂Ar), 4.15–4.22 (m, 2 H, CH₂N), 6.79 and 6.89 (s, 2 H, H-4,5, imidazole), 7.08 and 7.30 (m, 8 H, Ph).

¹³C NMR (100.62 MHz, CDCl₃): δ = 13.06 (Me), 28.65 (*C*H₂Ph), 30.46 (d, ${}^{1}J_{P-C}$ = 42.5 Hz, PCH₂CH₂N), 31.19 (Me), 32.68 (d, ${}^{1}J_{P-C}$ = 44.5 Hz, CH₂P), 34.29 (*C*Me), 40.92 (CH₂N), 118.88 (C-4, imidazole), 125.53 (*o*-C, Ph), 127.27 (C-5, imidazole), 127.75 (*m*-C, Ph), 136.44 (d, ${}^{3}J_{P-C}$ = 13.6 Hz, *i*-C, Ph), 144.17 (C-2, imidazole), 149.70 (*p*-C, Ph).

³¹P NMR (161.98 MHz, CDCl₃): δ = 34.90 (s + d satellites, ¹*J*_{P-Se} = 705 Hz).

⁷⁷Se NMR (76.31 MHz, CDCl₃): δ = -388.9 (d, ¹*J*_{P-Se} = 706 Hz).

Anal. Calcd for $C_{30}H_{43}N_2PSe: C, 66.53; H, 8.00; N, 5.17; P, 5.72; Se, 14.58. Found: C, 66.47; H, 8.04; N, 5.15; P, 5.43; Se, 14.50.$

[2-(1*H*-Benzo[*d*]imidazol-1-yl)ethyl]bis[4-(*tert*-butyl)phenethyl]phosphine Selenide (9i)

Colorless crystalline solid; yield (method A): 549 mg (95%); mp 170–173 $^{\circ}\mathrm{C}$ (hexane).

IR (KBr): 3093, 3054, 2962, 2865, 1615, 1493, 1461, 1363, 1283, 1268, 1247, 1199, 1163, 1142, 1108, 1009, 928, 865, 827, 811, 768, 745, 563, 430, 416 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): δ = 1.25 (s, 18 H, Me), 2.04–2.12 (m, 4 H, CH₂P), 2.28–2.39 (m, 2 H, PCH₂CH₂N), 2.68–2.87 (m, 4 H, CH₂Ph), 4.51–4.61 (m, 2 H, CH₂N), 6.10–7.43 (m, 10 H, H-5,6, imidazole, Ph), 7.44, 7.80 and 7.96 (m, 3 H, H-4,7,2, imidazole).

¹³C NMR (100.62 MHz, CDCl₃): δ = 28.36 (*C*H₂Ph), 28.90 (d, ¹*J*_{P-C} = 41.9 Hz, PCH₂CH₂N), 30.90 (Me), 32.53 (d, ¹*J*_{P-C} = 41.9 Hz, CH₂P), 34.04 (*C*Me), 39.84 (CH₂N), 109.08, 120.38 and 122.20 (C-7, 6, 5, imidazole), 125.25 (*o*-C, Ph), 127.52 (*m*-C, Ph), 132.70 (C-8, imidazole), 136.11 (d, ³*J*_{P-C} = 13.6 Hz, *i*-C, Ph), 142.62 and 143.58 (C-2, 9, imidazole), 149.35 (*p*-C, Ph).

³¹P NMR (161.98 MHz, CDCl₃): δ = 35.42 (s + d satellites, ¹*J*_{P-Se} = 709 Hz).

⁷⁷Se NMR (76.31 MHz, CDCl₃): δ = -391.8 (d, ¹*J*_{P-Se} = 709 Hz). Anal. Calcd for C₃₃H₄₃N₂PSe: C, 68.62; H, 7.50; N, 4.85; P, 5.36; Se, 13.67. Found: C, 68.59; H, 7.49; N, 4.79; P, 5.31; Se, 13.58.

[2-(1*H*-Imidazol-1-yl)ethyl]diphenylphosphine Selenide (9j) Light-yellow oil; yield (method A): 340 mg (95%).

IR (film): 3110, 3053, 2923, 2851, 1607, 1587, 1574, 1507, 1481, 1436, 1395, 1359, 1309, 1290, 1231, 1101, 1026, 997, 907, 845, 747, 692, 662, 623, 559, 541, 514, 495 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): $\delta = 2.97-3.04$ (m, 2 H, CH₂P), 4.35-4.41 (m, 2 H, CH₂N), 6.85 and 6.87 (s, 2 H, H-4,5, imidazole), 7.40-7.75 (m, 10 H, Ph), 7.94 (m, 1 H, H-2, imidazole).

¹³C NMR (100.62 MHz, CDCl₃): δ = 33.87 (d, ¹*J*_{P-C} = 47.5 Hz, CH₂P), 42.45 (CH₂N), 119.04 (C-4, imidazole), 128.90 (d, ³*J*_{P-C} = 12.5 Hz, *o*-C, Ph), 130.27 (d, ¹*J*_{P-C} = 79.6 Hz, *i*-C, Ph), 130.54 (C-5, imidazole), 131.30 (d, ²*J*_{P-C} = 10.7 Hz, *m*-C, Ph), 136.02 (d, ⁴*J*_{P-C} = 2.1 Hz, *p*-C, Ph), 136.64 (C-2, imidazole).

³¹P NMR (161.98 MHz, CDCl₃): δ = 30.50 (s + d satellites, ¹*J*_{P-Se} = 735 Hz).

⁷⁷Se NMR (76.31 MHz, CDCl₃): $\delta = -357.1$ (d, ¹ $J_{P-Se} = 735$ Hz).

Anal. Calcd for $C_{17}H_{17}N_2PSe: C, 56.83; H, 4.77; N, 7.80; P, 8.62; Se, 21.98. Found: C, 56.79; H, 4.72; N, 7.79; P, 8.59; Se, 21.93.$

[2-(1*H*-Benzo[*d*]imidazol-1-yl)ethyl]diphenylphosphine Selenide (9k)

Light-yellow oil; yield (method A): 368 mg (90%).

IR (film): 3054, 2988, 2916, 1647, 1614, 1587, 1495, 1459, 1436, 1383, 1369, 1333, 1311, 1284, 1241, 1200, 1159, 1100, 997, 910, 843, 800, 741, 692, 534, 493, 427 cm⁻¹.

¹H NMR (400.13 MHz, CDCl₃): δ = 3.04–3.11 (m, 2 H, CH₂P), 4.58–4.65 (m, 2 H, CH₂N), 6.85 and 6.87 (s, 2 H, H-5,6, imidazole), 7.31–7.36 and 7.64–7.70 (m, 11 H, H-4, imidazole, Ph), 7.72 and 7.92 (s, 2 H, H-7,2, imidazole).

¹³C NMR (100.62 MHz, CDCl₃): δ = 32.23 (d, ¹*J*_{P-C} = 48.7 Hz, CH₂P), 40.14 (CH₂N), 109.62 (C-7, imidazole), 120.13 (C-4, imidazole), 122.56 (C-6, imidazole), 123.24 (C-5, imidazole), 128.75 (d,

 ${}^{2}J_{P-C} = 12.4$ Hz, *o*-C, Ph), 130.27 (d, ${}^{1}J_{P-C} = 79.8$ Hz, *i*-C, Ph), 131.21 (d, ${}^{3}J_{P-C} = 10.9$ Hz, *m*-C, Ph), 131.94 (d, ${}^{4}J_{P-C} = 2.5$ Hz, *p*-C, Ph), 132.82, 142.73 and 142.92 (C-8, 2, 9, imidazole).

³¹P NMR (161.98 MHz, CDCl₃): δ = 30.69, (s + d satellites, ¹*J*_{P-Se} = 738 Hz).

⁷⁷Se NMR (76.31 MHz, CDCl₃): δ = -357.1 (d, ¹*J*_{P-Se} = 738 Hz).

Anal. Calcd for $C_{21}H_{19}N_2PSe: C, 61.62; H, 4.68; N, 6.84; P, 7.57; Se, 19.29.$ Found: C, 61.56; H, 4.66; N, 6.81; P, 7.53; Se, 19.21.

Acknowledgment

This work was carried out with financial support of leading scientific schools by the President of the Russian Foundation (grant NSH-3230.2010.3).

References

- (a) Grimmett, M. R. In *Comprehensive Heterocyclic Chemistry II*, Vol. 3; Katritzky, A. R.; Rees, C. W.; Scriven, E. F. V., Eds.; Pergamon: Oxford, **1996**, 77–220.
 (b) Hoffmann, H.; Lindel, T. *Synthesis* **2003**, 1753.
 (c) De Luca, L. *Curr. Med. Chem.* **2006**, *13*, 1. (d) Jin, Z. *Nat. Prod. Rep.* **2006**, *23*, 464. (e) Sivappa, R.; Hernandez, N. M.; He, Y.; Lovely, C. J. *Org. Lett.* **2007**, *9*, 3861.
 (f) Bellina, F.; Cauteruccio, S.; Rossi, R. *Tetrahedron* **2007**, *63*, 4571.
- (2) (a) Welton, T. Chem. Rev. 1999, 99, 2071.
 (b) Wasserscheid, P.; Keim, W. Angew. Chem. Int. Ed. 2000, 39, 3772. (c) Forsyth, S. A.; Pringle, J. M.; MacFarlane, D. R. Aust. J. Chem. 2004, 57, 113. (d) Chiappe, C.; Pieraccini, D. J. Phys. Org. Chem. 2005, 18, 275.
 (e) Rahman, T.; Fukuyama, T.; Ryu, I.; Suzuki, K.; Yonemura, K.; Hughes, P. F.; Nokihara, K. Tetrahedron Lett. 2006, 47, 2703. (f) Xu, J.-M.; Liu, B.-K.; Wu, W.-B.; Qian, C.; Wu, Q.; Lin, X.-F. J. Org. Chem. 2006, 71, 3991.
 (g) Greaves, T. L.; Drummond, C. J. Chem. Rev. 2008, 108, 206. (h) Plaquevent, J.-C.; Levillain, J.; Guillen, F.; Malhiac, C.; Gaumont, A.-C. Chem. Rev. 2008, 108, 5035.
- (3) (a) Ding, H.; Ma, C.; Yang, Y.; Wang, Y. Org. Lett. 2005, 7, 2125. (b) Pathan, M. Y.; Paike, V. V.; Pachmase, P. R.; More, S. P.; Ardhapure, S. S.; Pawar, R. P. ARKIVOC 2006, (xv), 205.
- (4) (a) Jalil, M. A.; Yamada, T.; Fujinami, S.; Hojo, T.; Nishikawa, H. *Polyhedron* 2001, *20*, 627. (b) Grotjahn, D. B.; Incarvito, C. D.; Rheingold, A. L. *Angew. Chem. Int. Ed.* 2001, *40*, 3884. (c) Harkal, S.; Rataboul, F.; Zapf, A.; Fuhrmann, C.; Riermeier, T.; Monsees, A.; Beller, M. *Adv. Synth. Catal.* 2004, *346*, 1742. (d) Grotjahn, D. B.; Gong,

Y.; Zakharov, L.; Golen, J. A.; Rheingold, A. L. J. Am. Chem. Soc. 2006, 128, 438. (e) Debono, N.; Canac, Y.;
Duhayon, C.; Chauvin, R. Eur. J. Inorg. Chem. 2008, 2991.
(f) Canac, Y.; Debono, N.; Vendier, L.; Chauvin, R. Inorg. Chem. 2009, 48, 5562. (g) Schulz, T.; Torborg, C.;
Schäffner, B.; Huang, J.; Zapf, A.; Kadyrov, R.; Börner, A.;
Beller, M. Angew. Chem. Int. Ed. 2009, 48, 918; Angew. Chem. 2009, 121, 936. (h) Field, L. D.; Messerle, B. A.;
Vuong, K. Q.; Turner, P. Dalton Trans. 2009, 3599.

- (5) Trofimov, B. A.; Malysheva, S. F.; Parshina, L. N.; Gusarova, N. K.; Belogorlova, N. A. Synlett 2011, 94.
- (6) (a) Gusarova, N. K.; Bogdanova, M. V.; Ivanova, N. I.; Chernysheva, N. A.; Sukhov, B. G.; Sinegovskaya, L. M.; Kazheva, O. N.; Alexandrov, G. G.; D'yachenko, O. A.; Trofimov, B. A. Synthesis 2005, 3103. (b) Sukhov, B. G.; Gusarova, N. K.; Ivanova, N. I.; Bogdanova, M. V.; Kazheva, O. N.; Alexandrov, G. G.; D'yachenko, O. A.; Sinegovskaya, L. M.; Malysheva, S. F.; Trofimov, B. A. J. Struct. Chem. 2005, 46, 1066. (c) Gusarova, N. K.; Malysheva, S. F.; Kuimov, V. A.; Belogorlova, N. A.; Mikhailenko, V. L.; Trofimov, B. A. Mendeleev Commun. 2008, 18, 260. (d) Trofimov, B. A.; Gusarova, N. K. Mendeleev Commun. 2009, 19, 295. (e) Malysheva, S. F.; Artem'ev, A. V.; Gusarova, N. K.; Timokhin, B. V.; Tatarinova, A. A.; Trofimov, B. A. Russ. J. Gen. Chem. 2009, 79, 1617. (f) Gusarova, N. K.; Malysheva, S. F.; Belogorlova, N. A.; Kazheva, O. N.; Chekhlov, A. N.; Alexandrov, G. G.; D'yachenko, O. A.; Sinegovskaya, L. M.; Trofimov, B. A. J. Struct. Chem. 2010, 51, 120.
- (7) (a) Leca, D.; Fensterbank, L.; Lacôte, E.; Malakria, M. *Chem. Soc. Rev.* 2005, *34*, 858. (b) Coudray, L.; Montchamp, J.-L. *Eur. J. Org. Chem.* 2008, 3601.
 (c) Trofimov, B. A.; Gusarova, N. K.; Chernysheva, N. A.; Yas'ko, S. V.; Kazantseva, T. I.; Ushakov, I. A. *Synthesis* 2008, 2743.
- (8) Jessop, C. M.; Parsons, A. F.; Routledge, A.; Irvine, D. J. Eur. J. Org. Chem. 2006, 1547.
- (9) (a) Gusarova, N. K.; Malysheva, S. F.; Oparina, L. A.; Belogorlova, N. A.; Tantsyrev, A. P.; Parshina, L. N.; Sukhov, B. G.; Tlegenov, R. T.; Trofimov, B. A. *ARKIVOC* 2009, (*vii*), 260. (b) Oparina, L. A.; Malysheva, S. F.; Gusarova, N. K.; Vysotskaya, O. V.; Stepanov, A. V.; Belogorlova, N. A.; Albanov, A. I.; Trofimov, B. A. *Synthesis* 2009, 3427.
- (10) (a) Shostakovskii, M. F.; Skvortsova, G. G.; Glazkova, N. P.; Domnina, E. S. *Chem. Heterocycl. Compd.* **1969**, 1070.
 (b) Mamashvili, T. N.; Keiko, N. A.; Kalikhman, I. D.; Domnina, E. S.; Glazkova, N. P.; Voronkov, M. G. *Russ. Chem. Bull.* **1987**, 2122.